PTC Therapeutics (PTCT) Misses Q4 EPS by 63c, Revenues Beat; Offers FY19 Revenue Guidance Below Consensus

PTC Therapeutics (NASDAQ: PTCT) reported Q4 EPS of ($0.96), $0.63 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $86.34 million versus the consensus estimate of $84.61 million.

"We are proud to be in the strong position of having a growing revenue base and robust pipeline with both small molecule and gene therapy programs,\" said Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. \"In our corporate presentation we have outlined our vision to develop these commercial and pipeline programs to achieve potential revenues of $1.5 billion by 2023."

GUIDANCE:

PTC Therapeutics sees FY2019 revenue of $285-305 million, versus the consensus of $314.8 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.

You May Also Be Interested In

• Fort Technology posts 49% revenue rise in first half of 2026
• RCM Technologies (RCMT) Tops Q2 EPS by 17c
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c